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Hereditary angioedema (HAE) is a group of rare, potentially life-threatening, and fre-
quently debilitating diseases characterized by recurrent, and often with an unpredictable 
onset, of swelling attacks. HAE is heterogeneous, with considerable differences between 
its subtypes, patients, and even within the same patient over time. During the past few 
years, several new on demand and prophylactic therapies have become available for 
HAE, allowing for individualized treatment. Therefore, to optimize HAE management, it is 
important to determine in all patients, the severity of their attacks, their disease activity, 
its therapeutic control, and its impact on their quality of life. In this manuscript, we review 
the existing tools to assess these aspects of HAE management, many of which are 
patient-reported outcome instruments. Also, we outline the current gaps of knowledge 
and what tools are still missing to allow for a comprehensive assessment of all patients 
with HAE including children.
Keywords: hereditary angioedema, severity, activity, impact, burden, quality of life, patient-reported outcomes, 
control
HOw HeReDiTARY ANGiOeDeMA (HAe) AFFeCTS PATieNTS 
AND wHY PHYSiCiANS NeeD TO ASSeSS SYMPTOM SeveRiTY, 
DiSeASe ACTiviTY, DiSeASe CONTROL, AND QUALiTY OF LiFe 
(QoL) iMPAiRMeNT iN THeiR PATieNTS
Hereditary angioedema is a group of rare, potentially life-threatening, and debilitating diseases 
characterized by recurrent swelling attacks. These attacks affect the skin and mucosa including the 
airway, gastrointestinal tract, and genitourinary region (1). Classically, the edema in HAE patients 
develops gradually over several hours, increases slowly for 12–36 h, and then subsides after 2–5 days 
if not fatal or treated. HAE may be severely debilitating and potentially life-threatening. Patients may 
experience painful abdominal attacks with a very sudden and severe onset as well as laryngeal edema 
Abbreviations: AAS, angioedema activity score; C1-INH, complement C1 inhibitor; HAE, hereditary angioedema; PRO, 
patient-reported outcome; QoL, quality of life.
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with acute airway obstruction. Attacks frequently occur after a 
trauma, and in the case of the airways, after events such as tooth 
extraction or tongue piercing (1).
Hereditary angioedema is a very heterogeneous disease with 
a fluctuating and unpredictable course (2–4). The frequency of 
attacks varies considerably between patients and within patients, 
from virtually never to twice weekly. HAE symptoms often begin 
in childhood and reoccur lifelong. In most families, other family 
members are affected, and many patients have ancestors who died 
of asphyxiation due to an HAE attack (5).
The classically described HAE types I and II are character-
ized by a deficiency of antigenic or functional complement C1 
inhibitor (C1-INH) and are referred to as C1-INH-HAE (6). More 
recently, HAE with normal C1-INH has been described as an 
estrogen-sensitive variant with a higher penetrance in women (6).
The variety of clinical manifestations, together with a com-
mon unfamiliarity among physicians and emergency staff, makes 
diagnosis, and treatment of this disorder particularly challenging. 
Based on these inherent diagnostic challenges, the mean delay to 
diagnosis can be as long as 16 years, even in developed countries 
(5, 7), with a decrease to 10.3 years more recently (8). In addition, 
patients may have difficulties in receiving proper treatments for 
acute HAE attacks as they are not available in all hospitals (9).
The burden of HAE includes physical, psychological, and social 
effects of the recurrent, unpredictable, disfiguring, painful, and 
potentially life-threatening attacks (10, 11). Additional emotional 
stress occurs when medical professionals fail to recognize the 
nature and severity of HAE, and when patients are not involved 
in the diagnostic and therapeutic process (12). In patients with 
untreated or inadequately controlled disease, a significant impact 
on work, school, and social activities is seen. In a Danish cohort 
study, more than half of patients felt that HAE had a significant 
psychological impact on their lives and subsequently, restricted 
their physical activities (8). Almost two-thirds worried about 
the risk of suffocation, and more than one-third worried about 
possible side effects of HAE treatment. Patients with HAE have 
higher levels of anxiety and depression than the background 
population (10–12).
Using the generic QoL questionnaires, SF-12 and SF-36, 
a reduced QoL in HAE patients was shown in many studies 
(10, 13–16). Between attacks, patients have a significant psycho-
social burden due to fear of the next painful abdominal attack 
or the possibility of a fatal laryngeal swelling (8, 11, 17). Many 
patients make long-term lifestyle modifications to accommodate 
their disease, with restrictions in their careers, partnerships, and 
recreational activities (10, 18). Furthermore, many patients have 
feelings of guilt about passing the disease to their children or 
decide not to have children (11, 19). Family members share the 
burden of patients, as they are often involved in the care of their 
relatives with HAE (20).
A conceptual model has been developed to illustrate the 
health-related QoL impacts of HAE (21). The model depicts 
five main areas of disease burden: unnecessary treatments and 
procedures, symptom triggers, attack impacts, caregiver impacts, 
and long-term impacts.
During the last 10 years, several new evidence-based and very 
effective treatments have become available. For the treatment of 
attacks, early therapy and self-administration are recommended 
and are now widely practiced in many countries (21). Long-term 
prophylaxis with intravenous plasma derived C1-INH has been 
introduced (22), and additional prophylactic treatment options 
are under development (23). An international guideline and con-
sensus papers have been published to promote evidence-based 
treatments (24–26). In many countries, comprehensive care cent-
ers have been established, with HAE specialists providing patients 
with tailored treatment, comprehensive disease management 
plans, and support at the psychosocial level (8, 17, 27–29). Recent 
studies show that the burden of illness improves significantly in 
HAE patients, who have access to newer therapies, expert care, 
and home therapy (8, 30).
In order to individualize and optimize the treatment of HAE 
patients, physicians need to understand their patients (i.e., the 
severity and frequency of attacks, the current disease activity, the 
impact of the disease on patients’ lives and QoL, as well as how 
well the disease is controlled). Attack severity, disease severity, 
disease activity, impact of the disease, and disease control are 
conceptually different but linked. Here, we review and discuss 
the importance of these different aspects of HAE and present the 
tools that are currently available to assess them.
HAe DiSeASe AND ATTACK SeveRiTY
Disease severity and disease activity, in HAE and in other chronic 
diseases, are different concepts. Disease severity relates to the 
overall disease experience of the patient. It includes the previous 
problems that the disease has imposed on the patient since its 
onset, the current burden of disease, and the long-term risks and 
prognosis, including the patient’s fears of potential problems to 
arise (31). In contrast, disease activity is the sum of the current 
problems (over a specified period of time) that a patient has expe-
rienced with his or her disease. Disease activity fluctuates, due to 
changes in the exposure to eliciting triggers and in response to 
treatment (32, 33). It can be precisely quantified, if appropriate 
tools are available, and is discussed in detail in the subsequent 
section. In contrast, disease severity tends to be more stable than 
activity, yet more difficult to classify and is discussed below.
The disease severity of HAE is difficult to classify for several 
reasons. First, disease activity likely alters disease severity. 
However, the disease activity of an individual HAE patient is 
highly variable over time, and, therefore, may not necessarily 
reflect the severity of HAE at a given time point (34). The avail-
ability of more tolerable and effective medications to prevent 
attacks and to treat attacks early after onset, likely alters disease 
activity and consequently HAE severity. Furthermore, classifying 
HAE disease severity is based upon subjective findings regarding 
a patient’s perception of the impact of disease on his or her QoL 
and on daily activities. To one patient, hand swellings may be 
perceived as insignificant, whereas to another, severe, as they 
impose major limitations in daily activities. Importantly, HAE is 
a disease in which all patients are at risk for an airway attack and 
death by asphyxiation, regardless of past symptoms, which makes 
it difficult to classify a disease as “mild.” Consequently, HAE is felt 
to be a severe disease in all patients given that all patients are at 
risk of developing laryngeal attacks and suffocation, even those 
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without previous laryngeal attacks. Finally, validated biomarkers 
that reliably measure disease severity are not available. As a result, 
creating an instrument for assessing HAE severity is difficult.
Tools to measure HAE disease severity have been proposed 
(19, 35–37). These tools vary in regards to which factors are 
addressed, including the age of symptom onset, sex, and attack 
locations, whether the patient used prophylactic therapy, dura-
tion and frequency of attacks, and the perceived impairment on 
daily activities. However, none of the reported tools to measure 
HAE severity have been validated, nor do they address the spe-
cific needs of pediatric or adolescent patients. They also vary in 
the recall period. In 2011, Bygum and coworkers reported the use 
of a clinical HAE severity score, based on the age at disease onset, 
the number of organs ever affected, and the need for long-term 
prophylaxis, with values from 0 to 10 (37). This score is not com-
monly applied in clinical practice. Another score was developed 
at the 2003 C1-Esterase Inhibitor Deficiency Workshop (36). This 
score includes the numbers of attacks in the past year (with each 
attack quantified by its impact on the patient’s ability to perform 
daily activities) and the need for treatment over the past year 
including emergency treatments and the use of long-term pro-
phylactic therapy. Although reported as a severity measure, this 
score, by and large, describes disease activity during the past year, 
with low- and high-cumulative values corresponding to low- and 
high-disease activity, respectively. In summary, HAE severity is 
hard to classify and, therefore, the development of validated tools 
remains a challenge.
In contrast, the assessment of the severity of a specific HAE 
attack is straightforward and several tools have been created and 
used. HAE guidelines recommend that patients and their pro-
viders monitor attack severity and attack frequency (6, 25, 28). 
Tools for quantifying attack severity are critical for clinical trials 
to quantify treatment effects on HAE attacks. Patient-reported 
outcome (PROs) measures such as the visual analog scales (VAS) 
have been used in trials for acute HAE therapy, and some of 
these scales have undergone content validation (38–40). VAS 
scores, although easy to compute, typically assess a single sign or 
symptom, and do not provide a composite score, yet would likely 
be able to be used by patients for their monitoring of an attack as 
part of their self-care.
Two additional measures have been developed to provide a 
composite score (41). The Mean Symptom Complex Severity 
(MSCS) is a global score incorporating the numbers of anatomi-
cal sites effected during an acute attack, termed the “symptoms 
complex” (e.g., hands and abdomen) and the patients’ assess-
ment of the severity of swelling at each site (e.g., none to severe). 
It measures the severity of an attack at a specified time point, such 
as at baseline, prior to administration of a study medication, or a 
time period after drug administration. The Treatment Outcome 
Score (TOS) is comprised of three components, the “symptoms 
complex,” the baseline severity, and the response at 4 and 24 h 
post-dosing. This score provides a numeric value to assess a 
patient’s response to therapy. Although the MSCS and the TOS 
are validated and address multiple anatomical locations of angi-
oedema during a specific attack, they are somewhat complex to 
calculate and not likely to be used for clinical practice. They have 
also been used for one medication, Ecallantide, and as a result, the 
scores cannot be used to compare it to other HAE medications 
not assessed by the TOS or MSCS. Taken together, PRO meas-
ures for assessing attack severity and frequency are available and 
valuable tools, as they allow for a standardized and reproducible 
documentation of HAE attacks over time. Attack severity should 
be assessed in routine clinical practice and in clinical trials.
HOw TO MeASURe DiSeASe ACTiviTY 
AND CONTROL iN HAe PATieNTS
Patient-reported outcome tools for assessing HAE activity are 
used to determine how active the disease is at a given point in 
time. Two validated PRO tools are readily available, the angi-
oedema activity score (AAS), and the hereditary angioedema 
activity score (HAE-AS) (42, 43).
The AAS is the first symptom-specific PRO measurement 
developed to assess angioedema activity. It is validated for all 
forms of recurrent angioedema including HAE. The AAS is a 
diary in which patients prospectively document on a daily basis, 
the presence or absence of angioedema during the past 24  h. 
If angioedema was present, patients answer five additional ques-
tions, each scored from 0 to 3 points. Thus, the minimum and 
maximum daily score can be between 0 and 15 points, respectively. 
Cumulative data from four consecutive weeks, labeled AAS28, 
provides a valid assessment of disease activity (42). The AAS has 
a one-dimensional structure, excellent internal consistency, good 
levels of validity, and test–retest reliability, and it is sensitive to 
changes of angioedema activity over time. Its minimal important 
difference is 8 points for the 7-day cumulative AAS (AAS7).
The HAE-AS is a specific PRO tool designed to assess dis-
ease activity in C1-INH-HAE (43). It was developed following 
psychometric and Rasch analysis and documents retrospective 
disease activity in the last 6 months. It consists of 12 items, which 
show unidimensionality. The raw score (0–29) is transformed 
into a linear measure with a scale from 0 to 30. This linear meas-
ure shows good internal consistency (Cronbach’s alpha 0.81), 
satisfactory reliability for group comparisons (Person separation 
index = 0.748), and good discriminative validity by age, gender, 
and disease severity (p < 0.05).
The AAS and the HAE-AS are similar in some aspects, yet 
different in others (see Table 1). Both tools are available free of 
charge to physicians for the use in routine clinical practice (AAS: 
www.moxie-gmbh.de; HAE-AS: www.idipaz.es). The AAS has 
been used in randomized controlled trials to assess angioedema 
activity (32, 44). Comparative studies that use both the AAS and 
HAE-AS are needed to better understand and compare the results 
obtained with these PRO tools.
Disease control is an important concept in chronic diseases, 
especially those characterized by recurrent attacks and fluctuat-
ing disease activity. Tools that assess disease control, determine 
the level of control that patients have of their disease at a specific 
time point. Examples of PRO measures that assess disease control 
are the asthma control test and the urticaria control test (45–48). 
Control tests can also be retrospective PRO measures and usu-
ally have defined cut off values that indicate poorly controlled 
disease. They are especially useful for assessing patient responses 
TAbLe 1 | Characteristics and availability of relevant patient-reported outcome measures for disease activity and QoL impairment in HAE.
HAe-AS AAS HAe-QoL Ae-QoL
Number of items (questions) 12 (once) 1–6 (everyday) 25 (once) 17 (once)
Recall period 6 months 1 day 6 months 4 weeks
Applicable in HAE 1/2 + + + +
Applicable in other forms of recurrent 
angioedema
− + − +
Assessment Retrospective Prospective Retrospective Retrospective
High level of patient compliance 
required
− + − −
Clinical important difference published − + − +
Cost-free use in routine patient 
management and investigator-initiated 
clinical research
+ + + +
Different language versions availablea American-
English, Spanish
American-English, Azeri, 
Canadian-English, Canadian-
French, Danish, Dutch, French, 
German, Greek, Hebrew, 
Hungarian, Italian, Japanese, 
Macedonian, Mexican-Spanish, 
Polish, Portuguese, Romanian, 
Russian, Slovakian, Spanish, 
Swedish, Turkish
Argentinien-Spanish, Austrian-
German, Brazilian-Portuguese, 
Canadian-English, Canadian-
French, Danish, French, German, 
Greek, Hebrew, Hungarian, 
Italian, Macedonian Mandarin-
Chinese, Polish, Romanian, 
Spanish, US-English, UK-English
American-English, Azeri, Canadian-
English, Canadian-French, Danish, 
Dutch, French, German, Greek, 
Hebrew, Hungarian, Italian, Japanese, 
Jordan-Arabic, Macedonian, Mexican-
Spanish, Polish, Portuguese, Puerto 
Rican-Spanish, Romanian, Russian, 
Slovakian, Spanish, Swedish, Turkish
AAS, angioedema activity score; AE-QoL, angioedema quality of life questionnaire; HAE-AS,  
hereditary angioedema activity score; HAE-QoL, hereditary angioedema quality of life questionnaire.
aAdditional language versions of the HAE-AS and HAE-QoL (check www.idipaz.es for updates)  
and the AAS and AE-QoL (check www.moxie-gmbh.de for updates) are in preparation.
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to preventive/prophylactic therapy, as they are quick to complete, 
can be used at every patient visit, and results are instantly avail-
able after completion. The development and validation of an 
angioedema control test is currently underway.
QoL iMPAiRMeNT iN HAe
Health-related quality of life (HRQoL) is the individual percep-
tion of the impact of a disease, disability, or symptom across 
physical, psychological, social, and somatic domains of function-
ing and well-being (49). Impaired HRQoL in patients with HAE 
has been documented by using generic instruments (e.g., SF-12, 
SF-36, and EQ-5D) (10, 14–16, 18, 50) and dermatology-specific 
questionnaires (DLQI) (51). Generic instruments (E5QD) have 
been used to estimate health status utilities (18, 32). Generic 
instruments (SF-12 and SF-36), dermatology instruments 
(DLQI), and pain instruments (pain disability index) have also 
been used to assess the effect an intervention has on HRQoL of 
patients with C1-INH-HAE (7, 52–54). Bouillet et al. found that 
HRQoL measured by SF-36 in patients with HAE was lower than 
in patients with allergy in France (p < 0.05) (14). More studies 
comparing HAE with other frequent and known diseases are 
needed. It is important to note that none of the generic PROs has 
been validated for its use in HAE.
Whereas generic questionnaires are useful for HRQoL com-
parison among different diseases, they often have a low sensitivity 
to assess particular facets of a disease (55). Therefore, condition-
specific questionnaires are usually preferable when evaluating 
the impact of individual diseases and their treatment on HRQoL 
impairment. Specific instruments, AE-QoL and HAE-QoL, are 
available and have been validated for angioedema and HAE, 
respectively (19, 56–58). One additional tool, the HAEA-QoL, is 
currently under development in the United States.
The AE-QoL is a symptom-specific questionnaire, which 
assesses HRQoL in patients older than 18 years with any type of 
recurrent angioedema (57). It consists of 17 items, which address 
four dimensions: functioning, fatigue/mood, fears/shame, and 
food. It has a recall period of 4 weeks. Its psychometric prop-
erties are good, with total internal consistency being 0.89 and 
test–retest reliability 0.83. It shows a total score value and four 
domain score values which vary from 0 to 100 after a linear trans-
formation of raw values. Higher score values indicate a lower 
HRQoL (57). AE-QoL is also sensitive to change, with a minimal 
clinical important difference of six points (58, 59). The AE-QoL 
has been used in some randomized clinical trials in bradykinin-
mediated and mast cell mediator-mediated angioedema (32, 
44, 59–61) and in clinical practice (59). Finally, AE-QoL is the 
recommended tool for assessing QoL in urticaria patients with 
angioedema in the EAACI/GA2LEN/EDF/WAO guideline for 
urticaria (62–64).
The HAE-QoL is a specific questionnaire for adult patients 
with C1-INH-HAE. It consists of 25 items grouped into seven 
HRQoL domains: treatment difficulties, physical functioning 
and health, disease-related stigma, emotional role and social 
functioning, concern about offspring, perceived control over 
illness, and mental health (19). It has been developed following a 
qualitative methodology, based on a patient-centered perspective 
(19, 56). It has a 6-month recall period. The HAE-QoL showed 
good internal consistency (Crombach’s alpha 0.92) and test–retest 
reliability (intraclass correlation coefficient 0.87), as well as a 
good discriminant validity in the psychometric analysis (19). 
HAE-QoL has been used in clinical practice (65).
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A summary of the validated PROs available used in HAE is 
shown in Table  1. Comparative studies between AE-QoL and 
HAE-QoL are needed to better understand differential proper-
ties of both PROs. Differences in the recall period and the aim of 
the assessment (treatment response, patient clinical follow-up) 
should be taken into account when choosing the most appropri-
ate PRO.
There is no validated specific PRO for the use in children with 
angioedema. As of now, there are only three published studies in 
which HRQoL was assessed in children with C1-INH-HAE. One 
used the Kidscreen-27 to study HRQoL in children from a big 
family with HAE in Colombia (50). The other used the Pediatric 
Quality of Life Inventory (PedsQL™) 4.0 Generic Core Scales 
(child self-report and maternal proxy report) to assess HRQoL in 
children with HAE from Hungary and Israel (66), while the third 
used PedsQL and the childrens DLQI (67).
Normalization of HRQoL should be a goal in patient care and 
treatment. HAE experts recommend that HRQoL be measured 
annually (6) and the World Allergy Organization C1-INH-HAE 
guidelines state that HRQoL should be considered when assess-
ing the need for maintenance treatment (25). In order to better 
quantify HRQoL in patients with C1-INH-HAE, its determinants 
and the effects that therapeutical interventions have on it, data on 
large populations are needed.
GAPS OF KNOwLeDGe, UNMeT NeeDS, 
AND CONCLUSiON
Hereditary angioedema is a variable and burdensome disease. 
All patients should be assessed for their disease activity, the 
frequency and severity of attacks, the impact of the disease on 
their daily lives, and their QoL, as well as the control of their 
disease at every visit. Today, validated tools are available for these 
measurements, with the exception of disease control, for which 
a specific tool is currently under development. Some of the tools 
available have been translated to several languages and culturally 
adapted, but further work is needed to make all tools available for 
all patients in all countries. Also, none of the available tools have 
been adapted or validated for their use in children and adoles-
cents. The development of PRO tools for children and adolescents 
with HAE, thus, remains an imminent unmet need. Also, many 
of the tools available, although developed in line with FDA and 
EMA requirements and recommendations, have yet to receive 
official approval by these regulatory authorities.
AUTHOR CONTRibUTiONS
All authors have contributed to the conception, development, 
drafting, and finalization of the manuscript.
ReFeReNCeS
1. Bork K, Barnstedt SE. Laryngeal edema and death from asphyxiation after 
tooth extraction in four patients with hereditary angioedema. J Am Dent Assoc 
(2003) 134:1088–94. doi:10.14219/jada.archive.2003.0323 
2. Bork K, Maurer M, Bas M, Hartmann K, Biedermann T, Kreuz W, et  al. 
Hereditäres angioödem durch C1-inhibitor-mangel. Allergo J (2012) 2:9. 
3. Speletas M, Szilagyi A, Psarros F, Moldovan D, Magerl M, Kompoti M, et al. 
Hereditary angioedema: molecular and clinical differences among European 
populations. J Allergy Clin Immunol (2015) 135:570–3. doi:10.1016/j.
jaci.2014.08.007 
4. Gomez-Traseira C, Perez-Fernandez E, Lopez-Serrano MC, Garcia-Ara MC, 
Pedrosa M, Lopez-Trascasa M, et  al. Clinical pattern and acute and long-
term management of hereditary angioedema due to C1-esterase inhibitor 
deficiency. J Investig Allergol Clin Immunol (2015) 25:358–64. 
5. Roche O, Blanch A, Caballero T, Sastre N, Callejo D, Lopez-Trascasa M. 
Hereditary angioedema due to C1 inhibitor deficiency: patient registry and 
approach to the prevalence in Spain. Ann Allergy Asthma Immunol (2005) 
94:498–503. doi:10.1016/S1081-1206(10)61121-0 
6. Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et  al. 
Classification, diagnosis, and approach to treatment for angioedema: consen-
sus report from the Hereditary Angioedema International Working Group. 
Allergy (2014) 69:602–16. doi:10.1111/all.12380 
7. Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. 
Br J Dermatol (2009) 161:1153–8. doi:10.1111/j.1365-2133.2009.09366.x 
8. Bygum A. Hereditary angioedema - consequences of a new treat-
ment paradigm in Denmark. Acta Derm Venereol (2014) 94:436–41. 
doi:10.2340/00015555-1743 
9. Jaiganesh T, Hughan C, Webster A, Bethune C. Hereditary angioedema: a sur-
vey of UK emergency departments and recommendations for management. 
Eur J Emerg Med (2012) 19:271–4. doi:10.1097/MEJ.0b013e32834c9e1f 
10. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. 
The humanistic burden of hereditary angioedema: impact on health-related 
quality of life, productivity, and depression. Allergy Asthma Proc (2010) 
31:407–14. doi:10.2500/aap.2010.31.3394 
11. Caballero T, Aygoren-Pursun E, Bygum A, Beusterien K, Hautamaki E, 
Sisic Z, et al. The humanistic burden of hereditary angioedema: results from 
the Burden of Illness Study in Europe. Allergy Asthma Proc (2014) 35:47–53. 
doi:10.2500/aap.2013.34.3685 
12. Fouche AS, Saunders EF, Craig T. Depression and anxiety in patients with 
hereditary angioedema. Ann Allergy Asthma Immunol (2014) 112:371–5. 
doi:10.1016/j.anai.2013.05.028 
13. Caballero T, Caminoa M, Prior N, Gomez-Traseira C, Perez E, Forjaz M, et al. 
Health-related quality of life in adult patients with hereditary angioedema due 
to C1 inhibitor deficiency (HAE-C1-INH) assessed by SF-36v2: preliminary 
results of an international study. Allergy (2011) 66:685–6.
14. Bouillet L, Launay D, Fain O, Boccon-Gibod I, Laurent J, Martin L, et  al. 
Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and 
quality of life of 193 French patients. Ann Allergy Asthma Immunol (2013) 
111:290–4. doi:10.1016/j.anai.2013.07.012 
15. Gomide MA, Toledo E, Valle SO, Campos RA, Franca AT, Gomez NP, et al. 
Hereditary angioedema: quality of life in Brazilian patients. Clinics (Sao Paulo) 
(2013) 68:81–3. doi:10.6061/clinics/2013(01)OA13 
16. Jindal NL, Harniman E, Prior N, Perez-Fernandez E, Caballero T, Betschel S. 
Hereditary angioedema: health-related quality of life in Canadian patients as 
measured by the SF-36. Allergy Asthma Clin Immunol (2017) 13:4. doi:10.1186/
s13223-016-0176-3 
17. Longhurst H, Bygum A. The humanistic, societal, and pharmaco-eco-
nomic burden of angioedema. Clin Rev Allergy Immunol (2016) 51:230–9. 
doi:10.1007/s12016-016-8575-2 
18. Nordenfelt P, Dawson S, Wahlgren CF, Lindfors A, Mallbris L, Bjorkander J. 
Quantifying the burden of disease and perceived health state in patients with 
hereditary angioedema in Sweden. Allergy Asthma Proc (2014) 35:185–90. 
doi:10.2500/aap.2014.35.3738 
19. Prior N, Remor E, Perez-Fernandez E, Caminoa M, Gomez-Traseira C, 
Gaya F, et al. Psychometric field study of hereditary angioedema quality of 
life questionnaire for adults: HAE-QoL. J Allergy Clin Immunol Pract (2016) 
4:464–73.e4. doi:10.1016/j.jaip.2015.12.010 
20. Aygoren-Pursun E, Bygum A, Beusterien K, Hautamaki E, Sisic Z, Wait S, et al. 
Socioeconomic burden of hereditary angioedema: results from the hereditary 
6Bygum et al. How to Assess HAE
Frontiers in Medicine | www.frontiersin.org December 2017 | Volume 4 | Article 212
angioedema burden of illness study in Europe. Orphanet J Rare Dis (2014) 
9:99. doi:10.1186/1750-1172-9-99 
21. Caballero T, Aberer W, Longhurst HJ, Maurer M, Zanichelli A, Perrin A, 
et  al. The Icatibant Outcome Survey: experience of hereditary angioedema 
management from six European countries. J Eur Acad Dermatol Venereol 
(2017) 31(7):1214–22. doi:10.1111/jdv.14251 
22. Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, et al. Nanofiltered 
C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl 
J Med (2010) 363:513–22. doi:10.1056/NEJMoa0805538 
23. Bork K. Current drugs in early development for hereditary angioedema: 
potential for effective treatment. Expert Opin Investig Drugs (2014) 23:887–91. 
doi:10.1517/13543784.2014.916275 
24. Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, et  al. 
Evidence-based recommendations for the therapeutic management of 
angioedema owing to hereditary C1 inhibitor deficiency: consensus report 
of an International Working Group. Allergy (2012) 67:147–57. doi:10.1111/ 
j.1398-9995.2011.02751.x 
25. Craig T, Aygoren-Pursun E, Bork K, Bowen T, Boysen H, Farkas H, et  al. 
WAO guideline for the management of hereditary angioedema. World Allergy 
Organ J (2012) 5:182–99. doi:10.1097/WOX.0b013e318279affa 
26. Jose J, Zacharias J, Craig T. Review of select practice parameters, evidence-based 
treatment algorithms, and international guidelines for hereditary angioedema. 
Clin Rev Allergy Immunol (2016) 51:193–206. doi:10.1007/s12016-016-8546-7 
27. Manson AL, Price A, Dempster J, Clinton-Tarestad P, Greening C, Enti R, et al. 
In pursuit of excellence: an integrated care pathway for C1 inhibitor deficiency. 
Clin Exp Immunol (2013) 173:1–7. doi:10.1111/cei.12083 
28. Zuraw BL, Banerji A, Bernstein JA, Busse PJ, Christiansen SC, Davis-Lorton M, 
et  al. US Hereditary Angioedema Association Medical Advisory Board 
2013 recommendations for the management of hereditary angioedema due 
to C1 inhibitor deficiency. J Allergy Clin Immunol Pract (2013) 1:458–67. 
doi:10.1016/j.jaip.2013.07.002 
29. Nasr IH, Manson AL, Al Wahshi HA, Longhurst HJ. Optimizing hereditary 
angioedema management through tailored treatment approaches. Expert Rev 
Clin Immunol (2016) 12:19–31. doi:10.1586/1744666X.2016.1100963 
30. Christiansen SC, Bygum A, Banerji A, Busse P, Li H, Lumry W, et al. Before 
and after, the impact of available on-demand treatment for HAE. Allergy 
Asthma Proc (2015) 36:145–50. doi:10.2500/aap.2015.36.3831 
31. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A, Gonzalez-
Aveledo L, Maurer M. Factors linked to disease severity and time to remission 
in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol 
(2017) 31:964–71. doi:10.1111/jdv.14221 
32. Aygoren-Pursun E, Bygum A, Beusterien K, Hautamaki E, Sisic Z, Boysen HB, 
et al. Estimation of EuroQol 5-dimensions health status utility values in hered-
itary angioedema. Patient Prefer Adherence (2016) 10:1699–707. doi:10.2147/
PPA.S100383 
33. Caballero T, Maurer M, Longhurst HJ, Aberer W, Bouillet L, Fabien V, et al. 
Triggers and prodromal symptoms of angioedema attacks in patients with 
hereditary angioedema. J Investig Allergol Clin Immunol (2016) 26:383–6. 
doi:10.18176/jiaci.0102 
34. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med (2008) 
359:1027–36. doi:10.1056/NEJMcp0803977 
35. Cumming SA, Halsall DJ, Ewan PW, Lomas DA. The effect of sequence varia-
tions within the coding region of the C1 inhibitor gene on disease expression 
and protein function in families with hereditary angio-oedema. J Med Genet 
(2003) 40:e114. doi:10.1136/jmg.40.10.e114 
36. Agostoni A, Aygoren-Pursun E, Binkley KE, Blanch A, Bork K, Bouillet L, et al. 
Hereditary and acquired angioedema: problems and progress: proceedings of 
the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin 
Immunol (2004) 114:S51–131. doi:10.1016/j.jaci.2004.06.047 
37. Bygum A, Fagerberg CR, Ponard D, Monnier N, Lunardi J, Drouet C. 
Mutational spectrum and phenotypes in Danish families with hereditary 
angioedema because of C1 inhibitor deficiency. Allergy (2011) 66:76–84. 
doi:10.1111/j.1398-9995.2010.02456.x 
38. Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, et  al. 
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. 
N Engl J Med (2010) 363:532–41. doi:10.1056/NEJMoa0906393 
39. Riedl MA, Bernstein JA, Li H, Reshef A, Lumry W, Moldovan D, et  al. 
Recombinant human C1-esterase inhibitor relieves symptoms of hereditary 
angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy 
Asthma Immunol (2014) 112:163–9.e161. doi:10.1016/j.anai.2013.12.004 
40. McMillan CV, Speight J, Relan A, Bellizzi L, Haase G, Cicardi M. Content 
validity of visual analog scales to assess symptom severity of acute angioedema 
attacks in adults with hereditary angioedema: an interview study. Patient 
(2012) 5:113–26. doi:10.2165/11597490-000000000-00000 
41. Vernon MK, Rentz AM, Wyrwich KW, White MV, Grienenberger A. 
Psychometric validation of two patient-reported outcome measures to assess 
symptom severity and changes in symptoms in hereditary angioedema. Qual 
Life Res (2009) 18:929–39. doi:10.1007/s11136-009-9509-8 
42. Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K, et  al. 
Development, validation, and initial results of the angioedema activity score. 
Allergy (2013) 68:1185–92. doi:10.1111/all.12209 
43. Caballero T, Ayala A, Caminoa M, Prior N, Pérez-Fernández E, Forjaz MJ. 
Development of a clinical activity score for hereditary angioedema with 
C1-inhibitor deficiency. J Angioedema (2015):28–9. 
44. Staubach P, Metz M, Chapman-Rothe N, Sieder C, Brautigam M, Canvin J, 
et  al. Effect of omalizumab on angioedema in H1-antihistamine-resistant 
chronic spontaneous urticaria patients: results from X-ACT, a randomized 
controlled trial. Allergy (2016) 71:1135–44. doi:10.1111/all.12870 
45. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et  al. 
Development of the asthma control test: a survey for assessing asthma control. 
J Allergy Clin Immunol (2004) 113:59–65. doi:10.1016/j.jaci.2003.09.008 
46. Weller K, Groffik A, Church MK, Hawro T, Krause K, Metz M, et  al. 
Development and validation of the Urticaria Control Test: a patient-reported 
outcome instrument for assessing urticaria control. J Allergy Clin Immunol 
(2014) 133:1365–72, 1372.e1–e6. doi:10.1016/j.jaci.2013.12.1076 
47. Garcia-Diez I, Curto-Barredo L, Weller K, Pujol RM, Maurer M, Gimenez-
Arnau AM. Cross-cultural adaptation of the urticaria control test from 
German to Castilian Spanish. Actas Dermosifiliogr (2015) 106:746–52. 
doi:10.1016/j.ad.2015.05.009 
48. Kulthanan K, Chularojanamontri L, Tuchinda P, Rujitharanawong C, Maurer M, 
Weller K. Validity, reliability and interpretability of the Thai version of the urti-
caria control test (UCT). Health Qual Life Outcomes (2016) 14:61. doi:10.1186/
s12955-016-0466-y 
49. Caballero T, Prior N. Burden of illness and quality-of-life measures in 
angioedema conditions. Immunol Allergy Clin North Am (2017) 37:597–616. 
doi:10.1016/j.iac.2017.04.005 
50. Sanchez MD, Cuervo J, Rave D, Clemen G, Yepes-Nunez JJ, Ortiz-Reyes B, 
et al. Hereditary angioedema in Medellin (Colombia): clinical evaluation and 
quality of life appraisal. Biomedica (2015) 35:419–28. doi:10.7705/biomedica.
v35i3.2417 
51. Poon E, Seed PT, Greaves MW, Kobza-Black A. The extent and nature of 
disability in different urticarial conditions. Br J Dermatol (1999) 140:667–71. 
doi:10.1046/j.1365-2133.1999.02767.x 
52. Kreuz W, Martinez-Saguer I, Aygoren-Pursun E, Rusicke E, Heller C, 
Klingebiel T. C1-inhibitor concentrate for individual replacement therapy in 
patients with severe hereditary angioedema refractory to danazol prophylaxis. 
Transfusion (2009) 49:1987–95. doi:10.1111/j.1537-2995.2009.02230.x 
53. Bewtra AK, Levy RJ, Jacobson KW, Wasserman RL, Machnig T, Craig TJ. 
C1-inhibitor therapy for hereditary angioedema attacks: prospective patient 
assessments of health-related quality of life. Allergy Asthma Proc (2012) 
33:427–31. doi:10.2500/aap.2012.33.3597 
54. Lumry WR, Miller DP, Newcomer S, Fitts D, Dayno J. Quality of life in patients 
with hereditary angioedema receiving therapy for routine prevention of 
attacks. Allergy Asthma Proc (2014) 35:371–6. doi:10.2500/aap.2014.35.3783 
55. Baiardini I, Bousquet PJ, Brzoza Z, Canonica GW, Compalati E, Fiocchi A, et al. 
Recommendations for assessing patient-reported outcomes and health-related 
quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper. 
Allergy (2010) 65:290–5. doi:10.1111/j.1398-9995.2009.02263.x 
56. Prior N, Remor E, Gomez-Traseira C, Lopez-Serrano C, Cabanas R, Contreras J, 
et al. Development of a disease-specific quality of life questionnaire for adult 
patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-
QoL): Spanish multi-centre research project. Health Qual Life Outcomes 
(2012) 10:82. doi:10.1186/1477-7525-10-82 
57. Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K, et  al. 
Development and construct validation of the angioedema quality of life 
questionnaire. Allergy (2012) 67:1289–98. doi:10.1111/all.12007 
7Bygum et al. How to Assess HAE
Frontiers in Medicine | www.frontiersin.org December 2017 | Volume 4 | Article 212
58. Weller K, Magerl M, Peveling-Oberhag A, Martus P, Staubach P, Maurer M. 
The Angioedema Quality of Life Questionnaire (AE-QoL)—assessment of 
sensitivity to change and minimal clinically important difference. Allergy 
(2016) 71:1203–9. doi:10.1111/all.12900 
59. Weller K, Kruger R, Maurer M, Magerl M. Subcutaneous self-injections of 
C1 inhibitor: an effective and safe treatment in a patient with hereditary 
angio-oedema. Clin Exp Dermatol (2016) 41:91–3. doi:10.1111/ced.12681 
60. Weller K, Maurer M, Fridman M, Supina D, Schranz J, Magerl M. Health-
related quality of life with hereditary angioedema following prophylaxis with 
subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy Asthma 
Proc (2017) 38:143–51. doi:10.2500/aap.2017.38.4025 
61. Staubach P, Metz M, Chapman-Rothe N, Sieder C, Brautigam M, Maurer M, 
et  al. Omalizumab rapidly improves angioedema-related quality of life in 
adult patients with chronic spontaneous urticaria: X-ACT study data. Allergy 
(2017). doi:10.1111/all.13339 
62. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, 
et al. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classifi-
cation, diagnosis, and management of urticaria: the 2013 revision and update. 
Allergy (2014) 69:868–87. doi:10.1111/all.12313 
63. Weller K, Zuberbier T, Maurer M. Chronic urticaria: tools to aid the diag-
nosis and assessment of disease status in daily practice. J Eur Acad Dermatol 
Venereol (2015) 29(Suppl 3):38–44. doi:10.1111/jdv.13200 
64. Weller K, Zuberbier T, Maurer M. Clinically relevant outcome measures for 
assessing disease activity, disease control and quality of life impairment in 
patients with chronic spontaneous urticaria and recurrent angioedema. Curr 
Opin Allergy Clin Immunol (2015) 15:220–6. doi:10.1097/ACI.00000000 
00000163 
65. Squeglia V, Barbarino A, Bova M, Gravante C, Petraroli A, Spadaro G, et al. High 
attack frequency in patients with angioedema due to C1-inhibitor deficiency 
is a major determinant in switching to home therapy: a real-life observational 
study. Orphanet J Rare Dis (2016) 11:133. doi:10.1186/s13023-016-0518-8 
66. Engel-Yeger B, Farkas H, Kivity S, Veszeli N, Kohalmi KV, Kessel A. Health-
related quality of life among children with hereditary angioedema. Pediatr 
Allergy Immunol (2017) 28:370–6. doi:10.1111/pai.12712 
67. Aabom A, Nguyen D, Fisker N, Bygum A. Health-related quality of life in 
Danish children with hereditary angioedema. Allergy Asthma Proc  (2017) 
38:440–46. doi:10.2500/aap.2017.38.4093 
Conflict of Interest Statement: PB: funding for clinical trials from CSL/Behring, 
Shire, Dyax, and BioCryst. AB has been involved in clinical research and educational 
events involving CSL-Behring, Jerini AG/Shire, Sobi, Dyax, and BioCryst. TC has 
been involved in clinical trials/clinical studies/registries, has been advisor, has been 
speaker and/or has received educational grants for BioCryst, CSL-Behring, Dyax, 
GSK, MSD, Novartis, Pharming Group NV, Shire HGT, and SOBI. MM: speaker 
and/or advisor and/or recipient of institutional funding of research/clinical trials: 
BioCryst, Dyax, Moxie, and Shire.
Copyright © 2017 Bygum, Busse, Caballero and Maurer. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
